期刊文献+

老年男性前列腺增生与血清25-羟维生素D水平的相关性研究 被引量:5

Relationship between prostatic hyperplasia and serum 25-hydroxy vitamin D level in elderly men
原文传递
导出
摘要 目的探讨血清25羟维生素D[25(OH)D。]与前列腺增生发生、发展的相关性。方法纳入北京大学人民医院老年科住院老年男性患者95例。测量血压、身高、体质量,计算体质指数(BMI),并检测血脂、空腹血糖(FPG)、血钙、前列腺特异性抗原(PSA)等指标,采用酶免疫分析法测定血清25(OH)D3水平。超声测量并计算前列腺体积(PV)及PV年增长率。结果95例老年男性血清25(OH)D3水平为12.1~83.9nmol/L,平均(35.5±15.2)nmol/L。血清25(OH)D3〉50nmol/L组老年男性患者PV低于25(OH)D3≤50nmol/L组[(31.5±6.0)ml与(39.9±14.5)ml,P〈0.0013;PV年增长率也低于25(0H)D3≤50nmol/L组[(o.4±0.2)ml/年与(O.5±0.4)ml/年,P〈0.013。相关分析结果显示,PV与血清25(OH)D3呈负相关(r=-0.207,P=0.044),与BMI、PSA呈正相关(r值分别为0.297、0.958,P=0.011和P〈0.001);PV年增长率也与BMI、PSA呈正相关(r值分别为0.316、0.464,p-0.007和P〈O.001),与血清25(OH)D。呈负相关,但差异无统计学意义(P〉0.05)。结论低水平血清25(OH)D。可能是前列腺增生的危险因素。 Objective To explore the relationship between serum 25-hydroxy vitamin D level and prostatic hyperplasia in elderly men. Methods Totally 95 male patients aged over 60 years were included. Blood pressure, body weight, body height, body mass index (BMI) were measured and calculated. Venous blood samples were obtained to determine fasting serum levels of 25-hydroxy vitamin D3 and blood glucose (FBG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), calcium and prostate specific antigen (PSA), total prostate volume(PV) and annual prostate growth rate were measured and calculated by ultrasound. Results The serum 25 (OH) D3 levels were varied from 12.1 nmol/ L to 83.9 nmol/L, with an average of (35.5±15.2) nmol/L in elderly male patients. PV growth rate were significantly lower in elderly men with 25 (OH) D3 〉50 nmol/L, than in elderly men with 25 (OH) D3≤50 nmol/L [(31.5±6.0) mlvs. (39.9 ± 14.5) ml, (0.4± 0.2) ml/yvs. (0.5 ± 0.4) ml/y, P〈0. 001 or 0.01]. PV was negatively correlated with serum 25-hydroxy vitamin D3 level (r= -0. 207, P〈0.05), and positively correlated with BMI and PSA (r=0. 297, 0. 958, P〈0.05 or and P〈0. 001). While annual prostate growth rate was positively correlated with BMI and PSA (r= 0. 316, 0. 464, P〈0.01 or d0. 001), and positively correlated with serum 25-hydroxy vitamin D3 level, but the difference was not statistically significant (P〉0.05). Conclusions I.ow serum 25- hydroxy vitamin D3 level may play a role in the pathogenesis of prostatic hyperplasia.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2014年第1期59-61,共3页 Chinese Journal of Geriatrics
关键词 前列腺增生 维生素D Prostatic hyperplasia Vitamin D
  • 相关文献

参考文献10

  • 1Haghsheno MA,Mellstr(o)m D,Behre CJ. Low 25-OH Vitamin D is associated with benign prostatic hyperplasia[J].{H}Journal Of Urology,2013.608-614.
  • 2Cava RC,Javier AN. Vitamin D deficiency[J].{H}New England Journal of Medicine,2007.1981-1982.
  • 3夏维波,李梅.维生素D缺乏的评价、预防及治疗——内分泌学会临床实践指南[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(2):144-146. 被引量:52
  • 4Barreto AM,Schwartz GG,Woodruff R. 25-hydroxyvitamin D3,the prohormone of 1,25-dihydroxy vitamin D3,inhibits the proliferation of primary prostatic epithelial cells[J].{H}Cancer Epidemiology Biomarkers & Prevention,2000.265-270.
  • 5Tiwari A. Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia[J].{H}Expert Opinion on Investigational Drugs,2007.1425-1439.
  • 6Huynh H,Pollak M,Zhang JC. Regulation of insulin-like growth factor (IGF) Ⅱ and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25 (OH)2D3 and its analog EB1089[J].{H}International Journal of Oncology,1998.137-143.
  • 7Bao BY,Ting HJ,Hsu JW. Protective role of l alpha,25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells[J].{H}International Journal of Cancer,2008.2699-2706.
  • 8Tiwari A. Elocalcitol,a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia,overactive bladder and male infertility[J].{H}DRUGS,2009.381-393.
  • 9Colli E,Rigatti P,Montorsi F. BXL628,a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia:a randomized clinical trial[J].{H}EUROPEAN UROLOGY,2006.82-86.
  • 10Taniguchi K,Katagiri K,Kashiwagi H. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model[J].J Steoid Biochem Mol Biol,2010.204-207.

共引文献51

同被引文献41

  • 1Kogawa M, Findlay DM, Anderson PH, et al. Osteoclastic metabolism of 25 (OH) -vitamin D3: a potential mechanism for optimization of bone resorption [ J ]. Endocrinol, 2010, 151(10) :4316-4625.
  • 2Holik MF.Vitamin D deficiency [ J] .N Engl J Med, 2007, 357 ( 3 ) : 266-281.
  • 3Wang TJ, Pencina M J, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease [ J ]. Circulation, 2008,117 (4) : 503-511.
  • 4So JY, Lee I-IJ, Smolarek AK, et al. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer [ J ]. Mol Pharmacol, 2011, 79 (3) : 360-367.
  • 5Asgari MM, Tang J, Warton ME, et al. Association of prediag- nostic serum vitamin D levels with the development of basal cell carcinoma [ J ] .J Invest Dermatol, 2010,130(5) : 1438-1443.
  • 6Kayaniyil S, Vieth R, Harris SB, et al. Association of 25 (OH) D and PTH with metabolic syndrome and its traditional and nontraditional components[J] .J Clin Endocrinol Metab, 2011,96 ( 1 ) : 168-175.
  • 7Haghsheno MA, Mellstrm D, Behre C J, et al. Low 25-0H vitamin D is associated with benign prostatic hyperplasia[ J]. J Urol, 2013,190(2) :608-614.
  • 8Bao BY, Ting HJ, Hsu JW, et al. Protactive role of 1a,25-dihydroxyvitamin D3 agaist oxidative stress in nonmalignant human prostate epithelial cells[J]. Int J Cacer, 2008, 122 (12) :2699-2706.
  • 9Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands [ J ] .J Clin Endo- crinol Metab, 2005,90 (2) : 962-972.
  • 10Nickel JC, Roehrborn CG, O'leary MP, et al. Examination of the relationship between symptoms of prostatitis and histo- logical inflammation: baseline data from the REDUCE che- moprevention trial[ J] .J Uro1,2007,178(3) :896-900.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部